A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs Lisaftoclax (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 31 Jul 2024 Planned initiation date changed from 1 Dec 2023 to 1 Oct 2024.
- 29 Dec 2023 New trial record